Hatteras Venture Partners

Type

Venture Capital

Status

Active

Location

Durham, United States

Total investments

112

Average round size

22M

Portfolio companies

64

Rounds per year

4.67

Lead investments

26

Follow on index

0.43

Exits

17

Stages of investment
SeedEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyPharmaceuticalsHealth CareHealth DiagnosticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsClinical Trials

Summary

Hatteras Venture Partners is the famous VC, which was founded in 2000. The venture was found in North America in United States. The main department of described VC is located in the Durham.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Hatteras Venture Partners, startups are often financed by Mountain Group Capital, Johnson & Johnson Development Corporation, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are Fletcher Spaght, Inc., Excelerate Health Ventures, New Enterprise Associates. In the next rounds fund is usually obtained by Mountain Group Capital, OUP (Osage University Partners), New Enterprise Associates.

The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline TetraLogic Pharmaceuticals, ORIG3N, Rodin Therapeutics Among the most popular fund investment industries, there are Medical, Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2018. Comparing to the other companies, this Hatteras Venture Partners performs on 13 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity.

The current fund was established by Clay B. Thorp, John Crumpler. Besides them, we counted 12 critical employees of this fund in our database.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtechHealthcare
Stage focus
Series ASeries B
Geo focus
United States

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 126800000
Fund raised date
2023-02-06

Analytics

Total investments
112
Lead investments
26
Exits
17
Rounds per year
4.67
Follow on index
0.43
Investments by industry
  • Biotechnology (79)
  • Health Care (59)
  • Medical (40)
  • Medical Device (33)
  • Therapeutics (27)
  • Show 49 more
Investments by region
  • United States (106)
  • Canada (5)
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
9
Avg. valuation at time of investment
1M
Group Appearance index
0.96
Avg. company exit year
9
Avg. multiplicator
0.27
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
AtaCor Medical 24 Apr 2024 Health Care, Medical Device Late Stage Venture 28M United States, California, San Clemente
RapidPulse 31 Aug 2022 Health Care, Medical Device Early Stage Venture 10M United States, Florida, Miami

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.